Aug. 14 at 2:02 PM
$SCNX [Read] The Company is scaling revenue on Arbli 500% QoQ and just introduced Rezenopy, its 2nd FDA approved drug for commercialization into an established infrastructure. The GM is 98% on this revenue, which is absolutely outstanding (IMO), and as production continues to scale on both Rezenopy and Arbli, margins will continue to improve, positive FCF and profitability. The management goal here is profitability in 2027, and a growth trajectory like this substantiates the claim - multiplier upside from this level intermediate term, as I have continued to emphasize for 12mos.
https://www.stocktitan.net/news/SCNX/scienture-reports-q2-2026-results-with-approximately-510-sequential-cfq4y49vho07.html
